Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Zhenying Tan-Wasielewski"'
Autor:
Elizabeth K. Lee, Zhenying Tan-Wasielewski, Ursula A. Matulonis, Michael J. Birrer, Alexi A. Wright, Neil Horowitz, Panagiotis A. Konstantinopoulos, Jennifer Curtis, Joyce F. Liu
Publikováno v:
Gynecologic Oncology Reports, Vol 29, Iss , Pp 118-122 (2019)
Peripheral neuropathy is a common side effect of chemotherapeutic agents that frequently necessitates dose-reduction, truncation of, or change in therapy. HDAC6 inhibition has demonstrated preclinical efficacy in preventing and/or reversing chemother
Externí odkaz:
https://doaj.org/article/01aa72ae4a484e6494a744f54209249b
Autor:
Elizabeth K. Lee, Zhenying Tan-Wasielewski, Carol Aghajanian, Robert L. Coleman, Jennifer Curtis, Michelle S. Hirsch, Ursula A. Matulonis, Lewis C. Cantley, Gordon B. Mills, L. Austin Doyle, Joyce F. Liu
Publikováno v:
Gynecologic Oncology Reports, Vol 32, Iss , Pp - (2020)
Platinum-resistant, recurrent, high grade epithelial ovarian carcinoma remains challenging to treat. Chemotherapy produces limited responses with modest survival benefits in the treatment of recurrent disease. In this context, targeted therapies may
Externí odkaz:
https://doaj.org/article/24282615b07b4f289616a02c35432ae1
Autor:
Tal Sella, Yue Zheng, Zhenying Tan‐Wasielewski, Shoshana M. Rosenberg, Philip D. Poorvu, Nabihah Tayob, Kathryn J. Ruddy, Shari I. Gelber, Rulla M. Tamimi, Lidia Schapira, Steven E. Come, Jeffrey M. Peppercorn, Virginia F. Borges, Ann H. Partridge, Jennifer A. Ligibel
Publikováno v:
Cancer. 128:3158-3169
Weight gain after a breast cancer diagnosis is common and is associated with inferior outcomes. Young survivors may be especially susceptible to weight changes given the impact of treatment on menopausal status.The authors identified women who were d
Autor:
Katya Losk, Alison Laws, Eric P. Winer, Zhenying Tan-Wasielewski, Lorenzo Trippa, Nan Lin, Tari A. King, Rachel A. Freedman, Olga Kantor, Elizabeth A. Mittendorf
Publikováno v:
Breast Cancer Research and Treatment. 185:215-227
In 2016, we initiated standardized “reflex” Oncotype DX Recurrence Score (RS) testing for patients ≤ 65 years with pT1-2N0-1 HR+/HER2− breast cancer. Here, we examine RS testing patterns, RS distribution, and factors associated with chemother
Autor:
Tianyu Li, Nan Lin, Elizabeth V. Lawler, Julieta Leone, Eric P. Winer, Sara M. Tolaney, Luke Walker, O. Metzger Filho, Rachel A. Freedman, Jerry Younger, William T. Barry, Lorenzo Trippa, Zhenying Tan-Wasielewski, Ian E. Krop
Publikováno v:
Annals of Oncology. 31:1231-1239
Background Brain metastases are frequent in HER2-positive breast cancer. ONT-380 (tucatinib) is a potent selective inhibitor of HER2 with intracranial activity in preclinical models. Patients and methods This was a phase I study of tucatinib with tra
Autor:
Meng X He, Jake Conway, Eric P. Winer, Geoffrey I. Shapiro, Bose Kochupurakkal, Ricardo G. Pastorello, Chelsea Andrews, Lorenzo Trippa, Eliezer M. Van Allen, Robert Godin, Beth Overmoyer, Elizabeth A. Mittendorf, Rie K. Tahara, Wafa Osmani, Tanya Keenan, Jennifer L. Guerriero, Sara M. Tolaney, Grace Winship, Zhenying Tan-Wasielewski, Adam Tracy
Publikováno v:
Cancer Research. 80:P3-10
Introduction: mTNBC progresses rapidly on first-line chemotherapy. For instance, in the TNT trial, median progression-free survival (PFS) was 3 months on first-line carboplatin. Selective inhibition of Wee1, a negative regulator of the G2 cell cycle
Autor:
Sara M. Tolaney, Eric P. Winer, Rebecca Rees, William T. Barry, Shom Goel, Lorenzo Trippa, Laura Spring, Sonia Pernas, Rie K. Tahara, Erica L. Mayer, Chelsea Andrews, Zhenying Tan-Wasielewski, Aditya Bardia
Publikováno v:
Clinical Breast Cancer. 19:399-404
Background Signaling through the cyclin-dependent kinase 4 and 6 (CDK4/6) pathway can mediate therapeutic resistance in HER2-positive breast cancer. Preclinical studies have demonstrated that CDK4/6 inhibitors can resensitize resistant HER2-positive
Autor:
Antonio C. Wolff, Kathy D. Miller, Kathryn P. Componeschi, Kirsten Timms, Rachel C. Jankowitz, Nadine Tung, Zhenying Tan-Wasielewski, Charles M. Perou, Andrea L. Richardson, Jennifer M. Specht, Vered Stearns, Ian E. Krop, Tiffany A. Traina, Mothaffar F. Rimawi, EP Winer, Lorenzo Trippa, Vandana G. Abramson, Erica L. Mayer, Paul K. Marcom, Lisa A. Carey, Carla I. Falkson
Publikováno v:
Ann Oncol
Background Cisplatin and paclitaxel are active in triple-negative breast cancer (TNBC). Despite different mechanisms of action, effective predictive biomarkers to preferentially inform drug selection have not been identified. The homologous recombina
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fd4d430b47b75126d84acfb82d53273f
https://europepmc.org/articles/PMC8437015/
https://europepmc.org/articles/PMC8437015/
Autor:
Michelle S. Hirsch, Gordon B. Mills, Robert L. Coleman, Carol Aghajanian, Ursula A. Matulonis, Elizabeth K. Lee, Lewis C. Cantley, Jennifer Curtis, Zhenying Tan-Wasielewski, L. Austin Doyle, Joyce F. Liu
Publikováno v:
Gynecologic Oncology Reports
Gynecologic Oncology Reports, Vol 32, Iss, Pp-(2020)
Gynecologic Oncology Reports, Vol 32, Iss, Pp-(2020)
Highlights • PI3K/AKT pathway alterations are frequently seen in ovarian cancer, providing rationale for targeted AKT inhibition. • AKT inhibitor MK-2206 in platinum resistant high grade serous ovarian cancer was notable for dermatologic toxicity
Autor:
Zhenying Tan-Wasielewski, Eric P. Winer, Jennifer R. Bellon, Jonathan D. Schoenfeld, Ricardo G. Pastorello, Tianyu Li, Wafa Osmani, Ian E. Krop, Romualdo Barroso-Sousa, Elizabeth A. Mittendorf, Edward T. Richardson, Lorenzo Trippa, Deborah A. Dillon, Chelsea Andrews, Sara M. Tolaney
Publikováno v:
Clinical breast cancer. 20(3)
Background The purpose of this study was to investigate whether combining pembrolizumab with palliative radiation therapy (RT) improves outcomes in patients with hormone receptor-positive (HR+) metastatic breast cancer (MBC). Patients and Methods Eli